ChromaDex Corporation - CDXC STOCK NEWS

ChromaDex Corp. (NASDAQ:CDXC) announced that its supplement, Tru Niagen^®, received the “Most Popular Brand of the Year Award” at the China International Natural Health & Nutrition Expo on September 20, 2022. This recognition highlights the product's robust research backing and expanding market presence, especially in the cross-border e-commerce sector in China. With a consumer base over 264 million aged 60 and above in China, the demand for healthy aging products is growing. ChromaDex aims to solidify its market leadership through partnerships and enhanced distribution channels.

ChromaDex has announced a new long-term commercial license and supply agreement with Nestlé Health Science that expands their previous supply agreement to include dietary supplements. The deal features a $1.975 million initial purchase commitment for the ingredient Niagen®, along with potential future milestone payments and tiered royalties based on sales. In addition, Nestlé is purchasing 3,816,794 shares of ChromaDex at $1.31 each for gross proceeds of $5 million.

ChromaDex Corp. (NASDAQ:CDXC) announced promising findings from a clinical study published in the Journal of the American College of Cardiology. The study evaluated the safety and tolerability of the company's proprietary Niagen® (nicotinamide riboside or NR) in Stage C heart failure patients. Key results showed that high-dose NR was well-tolerated, nearly doubling whole blood NAD+ levels, enhancing mitochondrial function, and reducing inflammatory markers. This milestone trial opens avenues for future research into NR's therapeutic potential in heart failure.

ChromaDex has established a joint venture to expedite the approval of Tru Niagen® registration in China ("Blue Hat" approval). An investment of $3M has been secured from existing strategic investors, including the CEO, Rob Fried. Cross-border sales of Tru Niagen® have begun successfully through Sinopharm Xingsha at the China International Natural Health & Nutrition Expo. The private placement for $3.1 million is expected to close around October 7, 2022, aimed at supporting health food registration and international expansion.

ChromaDex (NASDAQ:CDXC) announced the launch of Tru Niagen^® at the China International Natural Health & Nutrition Expo (NHNE) in Shanghai on September 20. This event will showcase Tru Niagen^® to over 100,000 distributors and retailers, reinforcing its status as a leader in NAD⁺ supplements. CEO Rob Fried indicated that the collaboration with Sinopharm Xingsha aims to expand cross-border sales and achieve regulatory approval in China. Tru Niagen^® has garnered multiple approvals internationally, further supporting its introduction into the Chinese market.

ChromaDex Corp. (NASDAQ:CDXC) partners with MyPharma2Go to introduce Tru Niagen® to Brazil, the first Latin American market for the product. This partnership enables cross-border sales of Tru Niagen® and Tru Niagen® PRO, which are based on the key ingredient nicotinamide riboside (NR), a leading NAD+ precursor. Both products are now available through Brazilian e-commerce platforms. With a track record of reaching over 240,000 patients, MyPharma2Go aims to enhance access to these supplements for healthy aging, supported by extensive clinical research backing Niagen®.

Ayana Bio has appointed Frank Jaksch as CEO, a veteran in the health and wellness industry, particularly known for founding ChromaDex, which develops the NAD product Tru Niagen (Nasdaq: CDXC). Launched in September 2021, Ayana Bio utilizes innovative plant cell technology to produce sustainable bioactives for consumer products, aiming to address challenges in ingredient supply chains exacerbated by climate change and geopolitical issues. The company, supported by Ginkgo Bioworks (NYSE: DNA), is positioned to revolutionize sourcing through standardized cultivation methods.

ChromaDex Corp. (NASDAQ: CDXC) announced a significant legal victory as the U.S. Patent Trial and Appeal Board rejected Thorne Research's attempt to invalidate U.S. Patent No. 8,197,807, exclusively licensed for compositions containing nicotinamide riboside (NR). This decision strengthens ChromaDex's position in a patent infringement lawsuit against Thorne Research. The company is known for its flagship ingredient, Niagen®, which is backed by extensive clinical research and approved by leading global regulatory agencies.

ChromaDex Corp. (NASDAQ:CDXC) reported Q2 2022 net sales of $16.7 million, a 5% decline year-over-year, primarily due to reduced shipments and lower sales from A.S. Watson impacted by COVID-19. Costs were managed effectively, with gross margin at 60%, despite inflationary pressures. A decrease in general and administrative expenses by $2 million is positive. The company's full-year outlook anticipates high single-digit revenue growth, a consistent gross margin, and a target to achieve cash flow break-even by Q4 2022, supported by e-commerce growth.